First Financial Bankshares Inc grew its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 245.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 14,069 shares of the company’s stock after buying an additional 10,000 shares during the period. First Financial Bankshares Inc’s holdings in AbbVie were worth $3,680,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in ABBV. Financial Freedom LLC bought a new position in AbbVie in the 3rd quarter valued at approximately $29,000. Burk Holdings LLC purchased a new stake in AbbVie during the 2nd quarter valued at $30,000. Marquette Asset Management LLC boosted its stake in AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares during the last quarter. IMG Wealth Management Inc. increased its holdings in shares of AbbVie by 3,060.0% in the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after purchasing an additional 153 shares in the last quarter. Finally, Principia Wealth Advisory LLC increased its holdings in shares of AbbVie by 38.9% in the 2nd quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after purchasing an additional 44 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.
Analyst Ratings Changes
Several research firms have recently weighed in on ABBV. Sanford C. Bernstein restated a “market perform” rating and issued a $275.00 price target on shares of AbbVie in a research note on Monday, November 2nd. BMO Capital Markets set a $315.00 price objective on AbbVie in a research report on Wednesday, November 4th. Wells Fargo & Company increased their price objective on AbbVie from $300.00 to $340.00 and gave the company an “overweight” rating in a research report on Monday, November 2nd. Argus lifted their price objective on AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Finally, Piper Sandler boosted their target price on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $297.85.
View Our Latest Report on AbbVie
AbbVie Trading Down 0.3%
Shares of ABBV stock opened at $294.18 on Tuesday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $302.93. The firm’s 50 day moving average is $276.27 and its 200 day moving average is $241.28. The stock has a market capitalization of $520.00 billion, a P/E ratio of 50.63, a P/E/G ratio of 1.34 and a beta of 0.20.
AbbVie (NYSE:ABBV – Get Free Report) last announced its earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. The business had revenue of $17.40 billion during the quarter, compared to analyst estimates of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $1.86 EPS. As a group, equities analysts predict that AbbVie Inc. will post 13.98 earnings per share for the current year.
AbbVie Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be given a dividend of $1.82 per share. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. This is a boost from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. AbbVie’s dividend payout ratio (DPR) is currently 125.30%.
Insider Buying and Selling
In related news, EVP Jeffrey Stewart sold 40,619 shares of the company’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the completion of the sale, the executive vice president owned 83,171 shares in the company, valued at approximately $24,419,005.60. This represents a 32.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.
AbbVie Company Profile
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Further Reading
- Five stocks we like better than AbbVie
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
